|
||||||||||||||||||||||||||||||||
|
Home
» Archive
» 2009
TDK conference 2009Buránszki Barbara - year 5 SzIE, Faculty of Veterinary Science, Department of Internal Medicine Supervisors: Noémi Tarpataki DVM, Melinda Terényi DVM The aim of our study was to evaluate the clinical and immunological effectiveness of a human vaccine (Gynevac suspension injection –containing different Lactobacillus strains) and specific immunotherapy (SIT) in the treatment of canine atopic dermatitis. We examined 44 dogs suffering from atopic dermatitis (AD) and 15 healthy dogs. At the first examination blood sampling has been happened in all the 59 dogs. The ratio of CD4+/CD8+ T-lymphocytes from the blood samples has been analyzed by flow cytometry. The results and their evaluation are included in the study. Seventeen of the 59 dogs had accepted to be followed up (to be examined and treated five times). CD4+/CD8+ T-lymphocytes ratio has been measured in all cases at all the five consultations. Thirteen dogs were suffering from AD, they were divided into three, the other 4, clinically healthy negative control dogs were divided into two groups. The groups and the averages of the first and last measurements of the different groups were the following (in bracket): 1st group: 2 atopic dogs receiving SIT (2.35; 2.74), 2nd group: 5 atopic animals receiving only Gynevac injection (1.41; 1.59), 3rd group: 6 atopic dogs that beside SIT have also received Gynevac injection (1.30; 1.31). From the group of the negative control dogs, 2 have only received physiological saline solution (4th group: 1.97; 1.51) and 2 healthy animals received Gynevac vaccination (2.01; 1.81). There was a significant difference (p<0,05) between the 1st and 3rd group’s first and last results differences. There was not any other significant difference between other group’s results. To follow the animals’ clinical signs we have used the standard system of CADESI (Canine Atopic Dermatitis Extent and Severity Index), furthermore a 5 scaled index, the pruritus score index. In the 1st group the CADESI decreased by 62.96% and the pruritus by 62.50%. In the 2nd group the CADESI decreased by 60.85% and the pruritus by 35.30% since in the 3rd group by 50.55% and by 59.10%, retrospectively. After evaluating the data found above we have concluded that it can be suggested to complete the SIT therapy with Gynevac injection, which have been supported by immunological parameters. As the number of patients examined during our research was relatively small we are unable to give an unambiguous conclusion based on the findings. Nevertheless as a new alternative therapy, Gynevac inj. can be suggested to apply in canine atopic dermatitis. List of lectures |